NCT06358599|Completed
Loading search results
Sponsor study identifier
observational
221
1 country
1
Study Start
January 7, 2021
Actual (reported)Primary Completion
October 20, 2023
Actual (reported)Study Completion
January 15, 2024
Actual (reported)The World Health Organization 2016 bladder tumor classification reported that the diagnosis of variant histology has increased from 6% to 33% in the last 2 decades, and there is an increasing interest in investigating the effects on disease management, treatment options, and survival outcomes in bladder tumors with variant histology. In bladder tumors, variant histology is known to be more aggressive and has a worse prognosis than pure urothelial cancer, and most cases are muscle invasive at diagnosis. Neoadjuvant cisplatin-containing combination chemotherapy is known to improves overall survival in patients with urothelial cancers. However, it is unclear whether patients with non-pure urothelial cancer (variant) histology will also benefit from neoadjuvant chemotherapy. The investigators aimed to evaluate the role of Neoadjuvant cisplatin-containing combination chemotherapy in the final treatment plan and its impact on survival in patients with bladder cancer who were diagnosed with variant histology in the radical cystectomy specimen.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 15, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 7, 2021
Actual (reported)October 20, 2023
Actual (reported)January 15, 2024
Actual (reported)March 13, 2024
Actual (reported)April 10, 2024
Actual (reported)Change in survival outcomes at postoperative 2-year follow-up in patients with variant histology who received neoadjuvant chemotherapy before radical cystectomy.
2 years from radical cystectomy surgery
Factors associated with worse survival outcomes in cox-regression analysis at 2-year follow-up of all patients with variant histology who underwent radical cystectomy.
2 years from radical cystectomy surgery
Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
multiple tertiary care clinics
Ankara Etlik City Hospital
Ankara, 06170, Turkey (Türkiye)
221 participants (actual enrollment reported by the registry).
First Submitted
March 13, 2024
First Posted
April 10, 2024
Study Start
January 7, 2021
Actual (reported)Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
Contact the study team to confirm eligibility.
Primary Completion
October 20, 2023
Actual (reported)Study Completion
January 15, 2024
Actual (reported)Last Updated
April 10, 2024
Record last verified: 2024-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: